A Phase 1 Study of LNCB74 in Advanced Solid Tumors
← catalyst calendarNCT06774963 · readout ≤ 133 d
Sponsored by NextCure, Inc. (industry) · NXTC — their whole pipeline →. With LigaChem Biosciences, Inc..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
145estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-07 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Breast Cancer
- Endometrial Cancer
- Biliary Tract Cancer
- Non-Small Cell Lung Cancer
- Advanced or Metastatic Solid Tumors
Intervention
- Drug: LNCB74
Primary outcomes
what the primary-completion date above is the date OFEvaluate the safety and tolerability of LNCB74
measured 24 months
Define a recommended Phase 2 dose (RP2D) of LNCB74
measured Up to 24 months
Permalink · NXTC's whole pipeline · Catalyst calendar · Every registered study · What changed